Moreover, real‐world clinical practice validated that breast cancer patients with low BGN levels, including those with bilateral breast cancer, were more likely to respond to neoadjuvant PD‐1 blockade combined with chemotherapy. Here, PDCD1 is linked to breast carcinoma.